U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H20O2
Molecular Weight 268.3502
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of DIETHYLSTILBESTROL

SMILES

CC\C(C1=CC=C(O)C=C1)=C(\CC)C2=CC=C(O)C=C2

InChI

InChIKey=RGLYKWWBQGJZGM-ISLYRVAYSA-N
InChI=1S/C18H20O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,19-20H,3-4H2,1-2H3/b18-17+

HIDE SMILES / InChI

Molecular Formula C18H20O2
Molecular Weight 268.3502
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/083003.pdf | https://en.wikipedia.org/wiki/Diethylstilbestrol | http://monographs.iarc.fr/ENG/Monographs/vol100A/mono100A-16.pdf

Diethylstilbestrol is a synthetic non-steroidal estrogen. It is used in the treatment of menopausal and postmenopausal disorders, prostate cancer and in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery. Diethylstilbestrol is a very potent full agonist of the estrogen receptors. At the cellular level, estrogens increase the synthesis of DNA, RNA, and various proteins in target tissues. Pituitary mass is also increased. Estrogens reduce the release of gonadotropin-releasing hormone from the hypothalamus, leading to a reduction in release of follicle-stimulating hormone and luteinizing hormone from the pituitary. Adverse effects are: breast pain or tenderness, enlargement of breasts, gynecomastia, peripheral edema and others. Estrogens may interfere with the effects of bromocriptine. Dosage adjustment may be needed. Concurrent use with estrogens may alter the metabolism and protein binding of the glucocorticoids, leading to decreased clearance, increased elimination half-life, and increased therapeutic and toxic effects of the glucocorticoids.

Originator

Sources: DOI: 10.1016/0305-7372(84)90049-5https://www.nature.com/articles/141247b0
Curator's Comment: Fosfestrol was developed in the research laboratories of Asta-Werke and introduced in 1952 for the therapy of metastasizing prostatic carcinoma under the name of Honvan.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Stilphostrol

Approved Use

Unknown

Launch Date

3.78691191E11
Primary
STILBESTROL

Approved Use

Used in the treatment of prostate cancer.

Launch Date

1.07567997E11
Preventing
STILBESTROL

Approved Use

Prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery.

Launch Date

1.07567997E11
Primary
STILBESTROL

Approved Use

It is used for the treatment of senile (atrophic) vaginitis.

Launch Date

1.07567997E11
Primary
STILBESTROL

Approved Use

It is used for the treatment of vulvar dystrophy.

Launch Date

1.07567997E11
Primary
STILBESTROL

Approved Use

Other therapeutic use of diethylstilbestrol was post menopause syndrome.

Launch Date

1.07567997E11
Primary
STILBESTROL

Approved Use

Drug is indicated for replacement therapy of estrogen deficiency associated with amenorrhea.

Launch Date

1.07567997E11
Primary
STILBESTROL

Approved Use

Drug is indicated for replacement therapy of estrogen deficiency associated with female hypogonadism.

Launch Date

1.07567997E11
Preventing
STILBESTROL

Approved Use

Drug is indicated for the prevention of osteoporosis.

Launch Date

1.07567997E11
Doses

Doses

DosePopulationAdverse events​
1104 mg 1 times / day multiple, intravenous
Recommended
Dose: 1104 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1104 mg, 1 times / day
Sources:
unhealthy, 56-87
n = 17
Health Status: unhealthy
Condition: prostate cancer
Age Group: 56-87
Sex: M
Population Size: 17
Sources:
Disc. AE: Vomiting...
AEs leading to
discontinuation/dose reduction:
Vomiting (1 patient)
Sources:
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 59
n = 1
Health Status: unhealthy
Condition: prostate cancer
Age Group: 59
Sex: M
Population Size: 1
Sources:
Disc. AE: Secondary adrenocortical insufficiency...
AEs leading to
discontinuation/dose reduction:
Secondary adrenocortical insufficiency
Sources:
120 mg 3 times / day multiple, oral
Recommended
Dose: 120 mg, 3 times / day
Route: oral
Route: multiple
Dose: 120 mg, 3 times / day
Sources:
unhealthy, 65
n = 47
Health Status: unhealthy
Condition: prostate cancer
Age Group: 65
Sex: M
Population Size: 47
Sources:
Disc. AE: Toxic reaction (NOS), Toxic reaction (NOS)...
AEs leading to
discontinuation/dose reduction:
Toxic reaction (NOS) (grade 2, 3 patients)
Toxic reaction (NOS) (grade 3, 2 patients)
Sources:
5.7 g 1 times / day multiple, intravenous
MTD
Dose: 5.7 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.7 g, 1 times / day
Co-administed with::
SALICYLIC ACID(200 mg; 1/day)
Sources:
unhealthy, 68
n = 21
Health Status: unhealthy
Condition: prostate cancer
Age Group: 68
Sex: M
Population Size: 21
Sources:
DLT: Nausea and vomiting, Nausea and vomiting...
Dose limiting toxicities:
Nausea and vomiting (grade 1, 13 patients)
Nausea and vomiting (grade 2, 4 patients)
Weight gain (2 patients)
Edema (2 patients)
Sources:
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
unhealthy, 70
n = 38
Health Status: unhealthy
Condition: prostate cancer
Age Group: 70
Sex: M
Population Size: 38
Sources:
Other AEs: Hypertension, Gynecomastia...
Other AEs:
Hypertension (5%)
Gynecomastia (38%)
Peripheral edema (32%)
Gastrointestinal discomfort (19%)
Deep vein thrombosis (8%)
Skin rash (5%)
Transaminases increased (2%)
Sources:
1104 mg 1 times / day multiple, intravenous
Dose: 1104 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1104 mg, 1 times / day
Co-administed with::
MEPERIDINE(75 mg; i.m; 1/day)
PROCHLORPERAZINE(12.5 mg; i.m; 1/day)
Sources:
unhealthy, 74
n = 17
Health Status: unhealthy
Condition: prostate cancer
Age Group: 74
Sex: M
Population Size: 17
Sources:
Other AEs: Nausea, Bone pain...
Other AEs:
Nausea (17 patients)
Bone pain (17 patients)
Perineal pain (1 patient)
Deep vein thrombosis (4 patients)
Sources:
4 g 1 times / day multiple, intravenous
RP2D
Dose: 4 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 g, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: prostate cancer
Sex: M
Sources:
AEs

AEs

AESignificanceDosePopulation
Vomiting 1 patient
Disc. AE
1104 mg 1 times / day multiple, intravenous
Recommended
Dose: 1104 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1104 mg, 1 times / day
Sources:
unhealthy, 56-87
n = 17
Health Status: unhealthy
Condition: prostate cancer
Age Group: 56-87
Sex: M
Population Size: 17
Sources:
Secondary adrenocortical insufficiency Disc. AE
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 59
n = 1
Health Status: unhealthy
Condition: prostate cancer
Age Group: 59
Sex: M
Population Size: 1
Sources:
Toxic reaction (NOS) grade 2, 3 patients
Disc. AE
120 mg 3 times / day multiple, oral
Recommended
Dose: 120 mg, 3 times / day
Route: oral
Route: multiple
Dose: 120 mg, 3 times / day
Sources:
unhealthy, 65
n = 47
Health Status: unhealthy
Condition: prostate cancer
Age Group: 65
Sex: M
Population Size: 47
Sources:
Toxic reaction (NOS) grade 3, 2 patients
Disc. AE
120 mg 3 times / day multiple, oral
Recommended
Dose: 120 mg, 3 times / day
Route: oral
Route: multiple
Dose: 120 mg, 3 times / day
Sources:
unhealthy, 65
n = 47
Health Status: unhealthy
Condition: prostate cancer
Age Group: 65
Sex: M
Population Size: 47
Sources:
Edema 2 patients
DLT
5.7 g 1 times / day multiple, intravenous
MTD
Dose: 5.7 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.7 g, 1 times / day
Co-administed with::
SALICYLIC ACID(200 mg; 1/day)
Sources:
unhealthy, 68
n = 21
Health Status: unhealthy
Condition: prostate cancer
Age Group: 68
Sex: M
Population Size: 21
Sources:
Weight gain 2 patients
DLT
5.7 g 1 times / day multiple, intravenous
MTD
Dose: 5.7 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.7 g, 1 times / day
Co-administed with::
SALICYLIC ACID(200 mg; 1/day)
Sources:
unhealthy, 68
n = 21
Health Status: unhealthy
Condition: prostate cancer
Age Group: 68
Sex: M
Population Size: 21
Sources:
Nausea and vomiting grade 1, 13 patients
DLT
5.7 g 1 times / day multiple, intravenous
MTD
Dose: 5.7 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.7 g, 1 times / day
Co-administed with::
SALICYLIC ACID(200 mg; 1/day)
Sources:
unhealthy, 68
n = 21
Health Status: unhealthy
Condition: prostate cancer
Age Group: 68
Sex: M
Population Size: 21
Sources:
Nausea and vomiting grade 2, 4 patients
DLT
5.7 g 1 times / day multiple, intravenous
MTD
Dose: 5.7 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 5.7 g, 1 times / day
Co-administed with::
SALICYLIC ACID(200 mg; 1/day)
Sources:
unhealthy, 68
n = 21
Health Status: unhealthy
Condition: prostate cancer
Age Group: 68
Sex: M
Population Size: 21
Sources:
Gastrointestinal discomfort 19%
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
unhealthy, 70
n = 38
Health Status: unhealthy
Condition: prostate cancer
Age Group: 70
Sex: M
Population Size: 38
Sources:
Transaminases increased 2%
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
unhealthy, 70
n = 38
Health Status: unhealthy
Condition: prostate cancer
Age Group: 70
Sex: M
Population Size: 38
Sources:
Peripheral edema 32%
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
unhealthy, 70
n = 38
Health Status: unhealthy
Condition: prostate cancer
Age Group: 70
Sex: M
Population Size: 38
Sources:
Gynecomastia 38%
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
unhealthy, 70
n = 38
Health Status: unhealthy
Condition: prostate cancer
Age Group: 70
Sex: M
Population Size: 38
Sources:
Hypertension 5%
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
unhealthy, 70
n = 38
Health Status: unhealthy
Condition: prostate cancer
Age Group: 70
Sex: M
Population Size: 38
Sources:
Skin rash 5%
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
unhealthy, 70
n = 38
Health Status: unhealthy
Condition: prostate cancer
Age Group: 70
Sex: M
Population Size: 38
Sources:
Deep vein thrombosis 8%
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
unhealthy, 70
n = 38
Health Status: unhealthy
Condition: prostate cancer
Age Group: 70
Sex: M
Population Size: 38
Sources:
Perineal pain 1 patient
1104 mg 1 times / day multiple, intravenous
Dose: 1104 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1104 mg, 1 times / day
Co-administed with::
MEPERIDINE(75 mg; i.m; 1/day)
PROCHLORPERAZINE(12.5 mg; i.m; 1/day)
Sources:
unhealthy, 74
n = 17
Health Status: unhealthy
Condition: prostate cancer
Age Group: 74
Sex: M
Population Size: 17
Sources:
Bone pain 17 patients
1104 mg 1 times / day multiple, intravenous
Dose: 1104 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1104 mg, 1 times / day
Co-administed with::
MEPERIDINE(75 mg; i.m; 1/day)
PROCHLORPERAZINE(12.5 mg; i.m; 1/day)
Sources:
unhealthy, 74
n = 17
Health Status: unhealthy
Condition: prostate cancer
Age Group: 74
Sex: M
Population Size: 17
Sources:
Nausea 17 patients
1104 mg 1 times / day multiple, intravenous
Dose: 1104 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1104 mg, 1 times / day
Co-administed with::
MEPERIDINE(75 mg; i.m; 1/day)
PROCHLORPERAZINE(12.5 mg; i.m; 1/day)
Sources:
unhealthy, 74
n = 17
Health Status: unhealthy
Condition: prostate cancer
Age Group: 74
Sex: M
Population Size: 17
Sources:
Deep vein thrombosis 4 patients
1104 mg 1 times / day multiple, intravenous
Dose: 1104 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1104 mg, 1 times / day
Co-administed with::
MEPERIDINE(75 mg; i.m; 1/day)
PROCHLORPERAZINE(12.5 mg; i.m; 1/day)
Sources:
unhealthy, 74
n = 17
Health Status: unhealthy
Condition: prostate cancer
Age Group: 74
Sex: M
Population Size: 17
Sources:
PubMed

PubMed

TitleDatePubMed
Serum lipid levels and thromboembolic complications during estrogen therapy of prostatic cancer.
1975
Effect of mesulergine on prolactin secretion and dopamine D2 receptors-adaptive changes in diethylstilbestrol-induced hyperplasia of the rat anterior pituitary.
1992 Mar
Effects of estrogenic agents on chitobiase activity in the epidermis and hepatopancreas of the fiddler crab, Uca pugilator.
1999 Feb
A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma.
1999 Jan
Sexual dimorphism in diethylstilbestrol-induced prolactin pituitary tumors in F344 rats.
2000 Aug
Sulfation of environmental estrogen-like chemicals by human cytosolic sulfotransferases.
2000 Jan 7
Differential estrogen receptor binding of estrogenic substances: a species comparison.
2000 Nov 15
Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ERbeta.
2000 Nov 17
Activation of a uterine insulin-like growth factor I signaling pathway by clinical and environmental estrogens: requirement of estrogen receptor-alpha.
2000 Sep
Diethylstilbestrol regulates trophoblast stem cell differentiation as a ligand of orphan nuclear receptor ERR beta.
2001 Apr 1
Increased exocytosis of secretory granules in contrast to reduced serum hormone levels in pituitary adenomas of humans and rats treated with dopamine agonist.
2001 Jun
Estrogen and xenoestrogens upregulate the brain aromatase isoform (P450aromB) and perturb markers of early development in zebrafish (Danio rerio).
2001 Jun
Uterine adenocarcinoma in mice treated neonatally with genistein.
2001 Jun 1
Assessment of oestrogenic potency of chemicals used as growth promoter by in-vitro methods.
2001 May
Modulation by estrogens and xenoestrogens of recombinant human neuronal nicotinic receptors.
2001 Nov 2
Uterine responsiveness to estradiol and DNA methylation are altered by fetal exposure to diethylstilbestrol and methoxychlor in CD-1 mice: effects of low versus high doses.
2002 Aug 15
Improvement of a sensitive enzyme-linked immunosorbent assay for screening estrogen receptor binding activity.
2002 Dec
Induction of reproductive tract developmental abnormalities in the male rat by lowering androgen production or action in combination with a low dose of diethylstilbestrol: evidence for importance of the androgen-estrogen balance.
2002 Dec
Developmental increases in rat hepatic microsomal UDP-glucuronosyltransferase activities toward xenoestrogens and decreases during pregnancy.
2002 Feb
Findings in female offspring of women exposed in utero to diethylstilbestrol.
2002 Feb
Metabolism of 2-hydroxy-4-methoxybenzophenone in isolated rat hepatocytes and xenoestrogenic effects of its metabolites on MCF-7 human breast cancer cells.
2002 Feb 20
Activation of estrogen receptor alpha and ERbeta by 4-methylbenzylidene-camphor in human and rat cells: comparison with phyto- and xenoestrogens.
2003 Apr 30
Cirrhosis with steatohepatitis following longterm stilboestrol treatment.
2003 Aug
The inhibitory effects of flavonoids and antiestrogens on the Glut1 glucose transporter in human erythrocytes.
2003 Dec 15
The immune system of geriatric mice is modulated by estrogenic endocrine disruptors (diethylstilbestrol, alpha-zearalanol, and genistein): effects on interferon-gamma.
2003 Dec 15
Diethylstilbestrol induces rat spermatogenic cell apoptosis in vivo through increased expression of spermatogenic cell Fas/FasL system.
2003 Feb 21
Oxidative DNA damage induced by toluene is involved in its male reproductive toxicity.
2003 Jan
Simulation of the different biological activities of diethylstilbestrol (DES) on estrogen receptor alpha and estrogen-related receptor gamma.
2003 Jan
Endocrine disrupting chemicals: interference of thyroid hormone binding to transthyretins and to thyroid hormone receptors.
2003 Jan 31
Long-lasting effects of lindane on mouse spermatogenesis induced by in utero exposure.
2003 Jan-Feb
Differential expression of c-fos and c-myc protooncogenes by estrogens, xenobiotics and other growth-stimulatory agents in primary rat hepatocytes.
2003 Mar
Prenatal exposure to estrogenic compounds alters the expression pattern of platelet-derived growth factor receptors alpha and beta in neonatal rat testis: identification of gonocytes as targets of estrogen exposure.
2003 Mar
Effects of endocrine disrupting compounds on the pathology and oestrogen receptor alpha and beta distribution in the uterus and cervix of ewe lambs.
2003 Nov
Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor.
2003 Oct
Neonatal diethylstilbestrol exposure induces persistent elevation of c-fos expression and hypomethylation in its exon-4 in mouse uterus.
2003 Oct
Sulfonation of environmental estrogens by zebrafish cytosolic sulfotransferases.
2003 Sep 12
Induction of vitellogenin synthesis in an Atlantic salmon (Salmo salar) hepatocyte culture: a sensitive in vitro bioassay for the oestrogenic and anti-oestrogenic activity of chemicals.
2003 Sep-Oct
Neonatal estrogenization leads to increased expression of cellular retinol binding protein 2 in the mouse reproductive tract.
2004 Apr
Comparison of the Hershberger assay and androgen receptor binding assay of twelve chemicals.
2004 Feb 15
Long-term alteration of gene expression without morphological change in testis after neonatal exposure to genistein in mice: toxicogenomic analysis using cDNA microarray.
2004 Mar
Modulation of AhR-mediated CYP1A1 mRNA and EROD activities by 17beta-estradiol and dexamethasone in TCDD-induced H411E cells.
2004 Mar
Diethylstilbestrol induces fish oocyte maturation.
2004 Mar 9
Small nuclear RING finger protein expression during gonad development: regulation by gonadotropins and estrogen in the postnatal ovary.
2004 May
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Intravenous: Initial: 600-1,200 mg/day via slow injection for 5-10 days, then 300 mg/day for 10-20 days.
360-480 mg 3 times/day. Maintenance: 120-240 mg 3 times/day.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: There was exposed three prostatic carcinoma cell lines (LNCaP, DU 145, and PC-3), three non-prostatic neoplastic cell lines (KB: epidermoid carcinoma, EJ: Bladder carcinoma, Daudi: Burkitt lymphoma), and one non-transformed embryonic fibroblast line (MRC-5) to diethylstilbestrol (DES), DES monophosphate, and DES diphosphate (DESDP), at levels comparable to those occurring in patients’ sera during DESDP infusions. At concentrations of 1–20 µg/ml the drugs showed marked, dose-dependent cytotoxicity towards all cell lines under study.
1–20 µg/ml
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:35:47 UTC 2023
Edited
by admin
on Fri Dec 15 16:35:47 UTC 2023
Record UNII
731DCA35BT
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIETHYLSTILBESTROL
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
Diethylstilbestrol [WHO-DD]
Common Name English
STILBETIN
Brand Name English
DIETHYLSTILBESTROL [ORANGE BOOK]
Common Name English
DIETHYLSTILBESTROL [IARC]
Common Name English
.ALPHA.,.ALPHA.'-DIETHYL-(E)-4,4'-STILBENEDIOL
Common Name English
STILBESTRO
Brand Name English
PHENOL 4,4'-(1,2-DIETHYL-1,2-ETHENEDIYL)BIS-, (E)-
Common Name English
NSC-3070
Code English
DIETHYLSTILBESTROL [MI]
Common Name English
STILBESTROL
Brand Name English
DIETHYLSTILBESTROL [USP-RS]
Common Name English
DIETHYLSTILBESTROL [EP MONOGRAPH]
Common Name English
DIETHYLSTILBESTROL [MART.]
Common Name English
DIETHYLSTILBESTROL [HSDB]
Common Name English
diethylstilbestrol [INN]
Common Name English
DIETHYLSTILBESTROL [VANDF]
Common Name English
DIETHYLSTILBESTROL [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
WHO-VATC QG03CC05
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
WHO-VATC QL02AA01
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
CFR 21 CFR 530.41
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
NCI_THESAURUS C2182
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
IARC Diethylstilbestrol
WHO-ATC L02AA01
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
WHO-ATC G03CB02
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
WHO-VATC QG03CB02
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
WHO-ATC G03CC05
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
Code System Code Type Description
DRUG CENTRAL
875
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
PRIMARY
SMS_ID
100000085041
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
PRIMARY
EPA CompTox
DTXSID3020465
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
PRIMARY
HSDB
3060
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
PRIMARY
FDA UNII
731DCA35BT
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
PRIMARY
CAS
56-53-1
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
PRIMARY
NSC
3070
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
PRIMARY
ChEMBL
CHEMBL411
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
PRIMARY
INN
388
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
PRIMARY
PUBCHEM
448537
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
PRIMARY
MERCK INDEX
m4418
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
PRIMARY Merck Index
WIKIPEDIA
DIETHYLSTILBESTROL
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-278-5
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
PRIMARY
RS_ITEM_NUM
1195001
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
PRIMARY
EVMPD
SUB07112MIG
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
PRIMARY
NCI_THESAURUS
C433
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
PRIMARY
CHEBI
41922
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
PRIMARY
DAILYMED
731DCA35BT
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
PRIMARY
MESH
D004054
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
PRIMARY
RXCUI
3390
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
PRIMARY RxNorm
DRUG BANK
DB00255
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
PRIMARY
IUPHAR
2801
Created by admin on Fri Dec 15 16:35:47 UTC 2023 , Edited by admin on Fri Dec 15 16:35:47 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Binding Assay
IC50
Related Record Type Details
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY